Elsevier

Life Sciences

Volume 48, Issue 14, 1991, Pages 1341-1350
Life Sciences

Minireview
Developmental toxicity of valproic acid

https://doi.org/10.1016/0024-3205(91)90430-JGet rights and content

Abstract

Valproic acid is a very effective anticonvulsant agent widely used in the management of various forms of epilepsy. Administration of the drug during pregnancy results in increased incidence of congenital abnormalities in both humans and experimental animals. In recent years, a significant number of research efforts have attempted to define the contributory role of valproic acid to the impairment of normal prenatal growth and development. The present report summarizes current knowledge that has emerged from clinical and research studies. The specific topics include: the placental transfer of valproic acid; the teratogenic potential; structure-teratogenicity and dose-response relationships; species and strain differences; biochemical changes evoked by the drug in the fetus.

References (99)

  • R.G. Dickinson et al.

    J. Pediatr.

    (1979)
  • H. Nau et al.

    J. Chromatogr.

    (1981)
  • H. Nau et al.

    Toxic. in Vitro

    (1988)
  • B. Dalens et al.

    J. Pediatr.

    (1980)
  • M.R. Gomez

    J. Pediatr.

    (1981)
  • S.A. Clay et al.

    J. Pediatr.

    (1981)
  • O.H. Stanley et al.

    Lancet

    (1982)
  • E. Robert et al.

    Lancet

    (1982)
  • T. Bjerkedal et al.

    Lancet

    (1982)
  • E. Robert et al.

    Lancet

    (1983)
  • P. Mastroiacovo et al.

    Lancet

    (1983)
  • D. Lindhout et al.

    Lancet

    (1984)
  • D. Lindhout et al.

    Lancet

    (1986)
  • E. Jager-Roman et al.

    J. Pediatr.

    (1986)
  • H. Nau et al.

    Lancet

    (1983)
  • T.J. Mast et al.

    Toxicology

    (1986)
  • P.E. Binkerd et al.

    Fund. Appl. Toxicol.

    (1988)
  • L.L. Ong et al.

    Fund Appl. Toxicol.

    (1983)
  • H. Nau et al.

    Fund. Appl. Toxicol.

    (1986)
  • R.S. Hauck et al.

    Toxicol. Lett.

    (1989)
  • W. Loscher et al.

    Eur. J. Pharmacol.

    (1984)
  • H. Nau

    Toxic. Appl. Pharmacol.

    (1985)
  • H. Nau

    Fund Appl. Toxicol.

    (1986)
  • R.W. Hurd et al.

    Lancet

    (1983)
  • M.E. Coakley et al.

    Biochem. Pharmacol.

    (1986)
  • M. Trotz et al.

    Life Sci.

    (1987)
  • C.M. Regan

    Brain Res.

    (1985)
  • M.L. Martin et al.

    Toxic. in Vitro

    (1988)
  • M.L. Martin et al.

    Brain Res.

    (1988)
  • G.W. Paulson et al.

    Arch. Neurol.

    (1981)
  • E.J. Lammer et al.

    Teratology

    (1987)
  • F.W. Alexander

    Arch. Dis. Child.

    (1979)
  • T. Ishizaki et al.

    Pediatr. Pharmacol.

    (1981)
  • H. Nau et al.

    J. Pharmacol. Exp. Ther.

    (1981)
  • H. Nau et al.

    Clin. Pharmacokinet.

    (1982)
  • S. Kaneko et al.

    Br. J. Clin. Pharmacol.

    (1983)
  • H. Nau et al.

    J. Pediatr.

    (1984)
  • T. Hirano et al.

    Adv. Epileptology

    (1989)
  • F. Albani et al.

    Epilepsia

    (1983)
  • F. Albani et al.

    Br. J. Clin. Pharmacol.

    (1984)
  • A. Monks et al.

    Br. J. Clin. Pharmacol.

    (1979)
  • H. Nau et al.

    J. Clin. Pharmacol.

    (1986)
  • D.W. Fowler et al.

    J. Pharmacol. Exp. Ther.

    (1989)
  • J.B. Isom et al.

    Clin. Res.

    (1980)
  • P. Eymard et al.

    J. Pharmacol.

    (1971)
  • H. Nau

    Teratology

    (1986)
  • H. Nau et al.

    Arch. Toxicol. Suppl.

    (1987)
  • EDITORIAL

    Lancet

    (1988)
  • S. Kaneko et al.

    Epilepsia

    (1988)
  • Cited by (32)

    • Role of environmental factors and epigenetics in autism spectrum disorders

      2020, Progress in Molecular Biology and Translational Science
      Citation Excerpt :

      How VPA impacts the brain is still not well understood in the adult and even less so in the developing brain, however there are two interesting known molecular effects of VPA: (1) VPA acts on the GABA-ergic system, (2) VPA modulates an important factor of epigenetic regulation: the protein histone deacetylase. As early as 1969, it was understood that VPA leads to an increase of GABA in the brain which might inhibit the abnormal neuronal activity in epileptic centers in the brain (reviewed in Hammond et al. 1981 and in Cotariu and Saidman 1991)137,138 acting most probably through indirect effect on the cerebral enzymes that participate in the regulation of GABA.139 In the mouse, low doses of VPA (125–290 mg/kg) elevate GABA concentrations in the brain at the level of the synaptic terminals140,141 and valproate increases the level of GABA in the cerebro-spinal fluid in human.142

    • A scale out approach towards neural induction of human induced pluripotent stem cells for neurodevelopmental toxicity studies

      2018, Toxicology Letters
      Citation Excerpt :

      For example, antiepileptic drugs direct their action towards targets located on the central nervous system (CNS), and their effects can induce negative effects on neurodevelopmental processes (Cotariu and Zaidman, 1991). The use of such compounds during pregnancy can increase the risk of malformations in the developing fetus, namely at the neural tube level, as well as growth retardation and microcephaly (Cotariu and Zaidman, 1991; 22). Valproic acid (VPA), for example, is an antiepileptic drug that is widely administered to treat neurologic disorders such as epilepsy and acute mania.

    • An adverse outcome pathway framework for neural tube and axial defects mediated by modulation of retinoic acid homeostasis

      2015, Reproductive Toxicology
      Citation Excerpt :

      These studies have proven useful in providing overall hazard information based on apical endpoints such as resorptions, prenatal death, growth retardation and malformations. Decades of experience with these studies have shown that the nature of apical endpoints cannot readily be extrapolated between species and not even between strains of the same species [2,8,9]. The relevance of apical animal findings for the human situation is therefore not always clear-cut.

    View all citing articles on Scopus
    View full text